2-Bromo-1-(3,3-dimethylpiperidin-1-yl)ethanone | 138280-22-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-Bromo-1-(3,3-dimethylpiperidin-1-yl)ethanone
• CAS: 138280-22-5
• 化学式: C₉H₁₆BrNO
• 分子量: 234.13
• InChiKey: NYSFZKXOXDNBRM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Pivalic acid 6-{2-[ethyl(4-hydroxybenzoyl)amino]-4-methoxyphenyl}-5,6,7,8-tetrahydronaphthalen-2-yl ester 、 2-Bromo-1-(3,3-dimethylpiperidin-1-yl)ethanone 以the title compound (17 mg) was obtained的产率得到6-{2-{{4-[2-(3,3-Dimethylpiperidin-1-yl)ethoxy]benzyl}ethylamino}-4-methoxyphenyl}-5,6,7,8-tetrahydronaphthalen-2-ol
  参考文献：
  名称：

  Selective Estrogen Receptor Modulator

  摘要：

  本发明提供一种由以下式（I）表示的化合物; [其中T表示单键，可能具有取代基的C1-C4烷基和类似物；式（I-1）表示单键或双键；A表示单键，可能具有取代基的双价5-至14-成员杂环基和类似物；Y表示单键和类似物；Z表示亚甲基基团和类似物；环G表示苯基团和类似物，可能与5-至6-成员环缩合并可能具有杂原子；Ra和Rb相同或不同，表示氢原子和类似物；W表示单键和类似物；R'表示1到4个独立的氢原子和类似物；R''表示1到4个独立的氢原子和类似物]或其盐或水合物。

  公开号：

  US20120004315A1
• 作为产物：
  描述：

  3,3-二甲基哌啶 、 sodium hydroxide 、 溴乙酰氯 在 ice 、 乙醚 、 柠檬酸 、 Brine 、 magnesium sulfate 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以to provide the title compound (420 mg)的产率得到2-Bromo-1-(3,3-dimethylpiperidin-1-yl)ethanone
  参考文献：
  名称：

  Selective Estrogen Receptor Modulator

  摘要：

  本发明提供一种由以下式（I）表示的化合物; [其中T表示单键，可能具有取代基的C1-C4烷基和类似物；式（I-1）表示单键或双键；A表示单键，可能具有取代基的双价5-至14-成员杂环基和类似物；Y表示单键和类似物；Z表示亚甲基基团和类似物；环G表示苯基团和类似物，可能与5-至6-成员环缩合并可能具有杂原子；Ra和Rb相同或不同，表示氢原子和类似物；W表示单键和类似物；R'表示1到4个独立的氢原子和类似物；R''表示1到4个独立的氢原子和类似物]或其盐或水合物。

  公开号：

  US20120004315A1

文献信息

• Selective estrogen receptor modulator
  申请人：Hamaoka Shinichi

  公开号：US20060116364A1

  公开（公告）日：2006-06-01

  The present invention provides a compound represented by the following formula [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; R a and R b are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R′ represents 1 to 4 independent hydrogen atoms and the like; and R″ represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof

  本发明提供了一种化合物，其表示为以下式子[其中T表示单键，C1-C4的烷基，可能带有取代基等；式(I-1)表示单键或双键；A表示单键，二价的5-至14-成员杂环基团，可能带有取代基等；Y表示单键等；Z表示亚甲基等；环G表示苯基团等，可与5-至6-成员环缩合并且可能具有杂原子；Ra和Rb相同或不同，表示氢原子等；W表示单键等；R'表示1至4个独立的氢原子等；R"表示1至4个独立的氢原子等]或其盐，或其水合物。
• 1,5-benzodiazepine derivatives having CCK and/or gastrin antagonistic
  申请人：Glaxo Wellcome Inc.

  公开号：US05585376A1

  公开（公告）日：1996-12-17

  The present invention relates to compounds of general formula (I) ##STR1## and physiologically acceptable salts thereof wherein the group NR.sub.1 R.sub.2 represents a 5-7 membered saturated heterocyclic ring which may be substituted by one or two methyl groups; R.sub.3 is C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl or phenyl optionally substituted by 1 or 2 halogen atoms; R.sub.4 is phenyl or phenyl substituted by one or two groups selected from the group consisting of halogen, C.sub.1-4 alkyl, trifluoromethyl, trifluoromethoxy or (CH.sub.2).sub.n R.sub.5 wherein n is zero or 1 and R.sub.5 represents C.sub.1-4 alkoxy, hydroxy, nitro, cyano, CO.sub.2 R.sub.6, S(O).sub.p CH.sub.3, NR.sub.7 R.sub.8, CONR.sub.7 R.sub.8, SO.sub.2 NR.sub.7 CO(C.sub.1-4)alkyl, tetrazolyl, carboxamidotetrazolyl, or a 3-trifluoromethyl 1,2,4-triazolyl; R.sub.6 is hydrogen, C.sub.1-4 alkyl or benzyl; R.sub.7 is hydrogen or C.sub.1-4 alkyl, R.sub.8 is hydrogen, C.sub.1-4 alkyl, SO.sub.2 CH.sub.3 or SO.sub.2 CF.sub.3, X represent hydrogen, C.sub.1-4 alkyl or halogen; m is zero, 1 or 2, and p is zero, 1 or 2. The invention also relates to processes for preparation of these compounds and to their use in medicine as antagonists of gastrin and CCK.

  本发明涉及一般式(I)的化合物及其生理上可接受的盐 其中，基团NR1R2表示一个5-7成员饱和杂环环，可以被一个或两个甲基基团取代；R3是C1-6烷基，C3-6环烷基或苯基，可以选择地被1或2个卤素原子取代；R4是苯基或苯基，被选自卤素，C1-4烷基，三氟甲基，三氟甲氧基或(CH2) n R5的一种或两种基团取代，其中n为零或1，R5表示C1-4烷氧基，羟基，硝基，氰基，CO2R6，S（O）pCH3，NR7R8，CONR7R8，SO2NR7CO（C1-4）烷基，四唑基，羧酰基四唑基或3-三氟甲基1,2,4-三唑基；R6是氢，C1-4烷基或苄基；R7是氢或C1-4烷基，R8是氢，C1-4烷基，SO2CH3或SO2CF3；X表示氢，C1-4烷基或卤素；m为零，1或2，p为零，1或2。本发明还涉及制备这些化合物的方法以及它们在医学中作为胃泌素和CCK的拮抗剂的用途。
• SELECTIVE ESTROGEN RECEPTOR MODULATOR
  申请人：Hamaoka Shinichi

  公开号：US20090325930A1

  公开（公告）日：2009-12-31

  The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; (I-1) formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; R a and R b are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R′ represents 1 to 4 independent hydrogen atoms and the like; and R″ represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.

  本发明提供了一种由以下式（I）表示的化合物；[其中，T表示单键，C1-C4烷基，可以有取代基等；（I-1）式（I-1）表示单键或双键；A表示单键，双价的5-至14-成员杂环基，可以有取代基等；Y表示单键等；Z表示亚甲基等；环G表示苯基等，可以与5-至6-成员环缩合，可以有杂原子；Ra和Rb相同或不同，表示氢原子等；W表示单键等；R′表示1至4个独立的氢原子等；R″表示1至4个独立的氢原子等]或其盐，或其水合物。
• SELECTIVE ESTROGEN RECEPTOR MODULATORS
  申请人：Eisai Co., Ltd.

  公开号：EP1577288A1

  公开（公告）日：2005-09-21

  The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; Ra and Rb are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R' represents 1 to 4 independent hydrogen atoms and the like; and R" represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.

  本发明提供了由下式（I）代表的化合物； [其中 T 代表单键、可能具有取代基的 C1-C4 亚烷基等； 式（I-1）代表单键或双键；A 代表单键、可具有取代基等的二价 5 至 14 元杂环基团；Y 代表单键等；Z 代表亚甲基等；环 G 代表可与 5 至 6 元环缩合且可具有杂原子的亚苯基等；Ra和Rb彼此相同或不同，代表氢原子等；W代表单键等；R'代表1至4个独立氢原子等；R "代表1至4个独立氢原子等]或其盐或其水合物。
• Selective estrogen receptor modulators
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP1577288B1

  公开（公告）日：2014-07-23